Teva has entered into an agreement with Ortho-McNeil-Janssen to settle the patent infringement lawsuit in the US District Court for the District of New Jersey. It is related to Teva’s generic version of the oral contraceptive, Ortho Tri-Cyclen Lo.
Under the terms of the settlement, Teva will obtain a release for past sales of its generic product, in exchange for an undisclosed royalty payment.
The company will also obtain a license to re-enter the market on December 31, 2015, or earlier in certain circumstances.
Reportedly, the settlement will not become effective until the court enters a proposed consent judgment upholding the validity and enforceability of Ortho’s patent.